Sign inJoin waitlistJoin the waitlist

Daniel Landi

Associate Professor of Pediatrics · Duke University Hospital

Credentials: · · ·

History

Duke University Hospital
Present
Duke University Hospital
Present

Baylor University Hospital
2016–2017
Pediatric Hematology Oncology
Baylor University Hospital
2013–2016
Pediatrics
Duke University Hospital
2009–2012
University of Colorado School of Medicine
2005–2009

Research

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial
JAMA Oncology · 2017 · 747 citations
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Journal of Clinical Investigation · 2016 · 595 citations
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Nature Medicine · 2024 · 168 citations

David Ashley
9 papers
Meenakshi Hegde
7 papers
Nabil Ahmed
7 papers
Kevin Bielamowicz
5 papers · 2 as a fellow
AF
Andrea Franson
4 papers
Annick Desjardins
4 papers
Bridget Archambault
4 papers
DB
Darell Bigner
4 papers
Nicholas Whipple
4 papers
Nirmish Shah
4 papers
Stephen Gottschalk
4 papers
Susan Chi
4 papers

Grants

Phase 2 Trial of a Novel Peptide Vaccine Targeting CMV Antigen for Newly Diagnosed Pediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma
Food and Drug Administration · R01
Contact PI · $1.4M · Duke University
2021–2027

Clinical trials

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Principal investigator · Recruiting · Phase 1, Phase 2
Darell Bigner
2023–2028
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
Principal investigator · Completed · Phase 1
Gary Archer Ph.D.
2018–2020
PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
Principal investigator · Active not recruiting · Phase 1
Daniel Landi
2018–2027
Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
Principal investigator · Terminated · Phase 1
Gary Archer Ph.D.
2018–2020